Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia.
about
A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia.Inhibition of Aurora-B suppresses HepG2 cell invasion and migration via the PI3K/Akt/NF-κB signaling pathway in vitroPI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors.Knockdown of Aurora-B inhibits the growth of non-small cell lung cancer A549 cells.Cell cycle proteins as promising targets in cancer therapyThe Aurora kinase A inhibitor TC-A2317 disrupts mitotic progression and inhibits cancer cell proliferation.Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor.The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cellsPLK1 (polo like kinase 1) inhibits MTOR complex 1 and promotes autophagy.Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia.Healthy CD4+ T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia.Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia.The anticipating value of PLK1 for diagnosis, progress and prognosis and its prospective mechanism in gastric cancer: a comprehensive investigation based on high-throughput data and immunohistochemical validation.The polo-like kinase 1 inhibitor volasertib synergistically increases radiation efficacy in glioma stem cells.Expression and prognostic value of cell-cycle-associated genes in gastric adenocarcinoma.
P2860
Q33167422-5BB53699-9830-4081-95E8-65D5A83C5A11Q33962378-234B729B-30BA-4A3E-9798-9B2A336599D7Q35833018-B34B920E-1E8A-4196-83C2-BC751D5E8BBCQ35944474-FB79A076-7D1A-4050-AB00-0CABC5F1BB95Q37693690-7F2E92EB-7BE4-4849-AC09-442839306C08Q37709004-B3564AD4-80FD-492B-8910-5A4DBD4E1C5AQ38824242-77E8DCE8-196D-4C4D-943B-792257AADDA1Q38871688-5593E01A-2414-41E4-8A4D-A7319FC81ADEQ39012724-BC723F8A-BB58-4036-A547-04BE2409F2C9Q41904096-B55A59AD-FBA2-4B97-ACB5-BE32F38084F3Q42317505-F773B09A-3A1B-41C9-A903-46C720D89F03Q42440865-E5D43852-AC6C-40B4-ACC0-E3F3AFCE24D0Q47143539-8380C488-8E8E-4574-8B4E-8DE34E0ABE66Q52726729-88B85BEC-3C94-4652-8C2B-FB8C2F89528AQ55416570-63E702B3-6621-408E-888E-49642D15CFA9
P2860
Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Therapeutic targeting of Polo- ...... acute lymphoblastic leukemia.
@ast
Therapeutic targeting of Polo- ...... acute lymphoblastic leukemia.
@en
type
label
Therapeutic targeting of Polo- ...... acute lymphoblastic leukemia.
@ast
Therapeutic targeting of Polo- ...... acute lymphoblastic leukemia.
@en
prefLabel
Therapeutic targeting of Polo- ...... acute lymphoblastic leukemia.
@ast
Therapeutic targeting of Polo- ...... acute lymphoblastic leukemia.
@en
P2093
P2860
P50
P356
P1433
P1476
Therapeutic targeting of Polo- ...... acute lymphoblastic leukemia.
@en
P2093
Alberto M Martelli
Alessandra Cappellini
Alice Bertaina
Antonino Maria Spartà
Cecilia Evangelisti
Daniela Bressanin
Fraia Melchionda
P2860
P304
P356
10.4161/CC.29267
P577
2014-05-29T00:00:00Z